News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Mohamad Mohty shares long-term survival outcomes from the phase II MagnetisMM-3 study – Multiple Myeloma Hub
Photo from Mohamad Mohty/X
Jun 20, 2024, 11:53

Mohamad Mohty shares long-term survival outcomes from the phase II MagnetisMM-3 study – Multiple Myeloma Hub

Multiple Myeloma Hub shared on X/Twitter:

“CONGRESS | POSTER | EHA2024 | Mohamad Mohty shares long-term survival outcomes from the phase II MagnetisMM-3 study of elranatamab in patients with RRMM, N=123. ORR remained at 61%, with median DoR not reached.”

Source: Multiple Myeloma Hub/X

cancer EHA2024 elranatamab MagnetisMM-3 Mohamad Mohty Multiple Myeloma Hub OncoDaily Oncology RRMM
Insight
Jul 1, 2024, 09:25
Sylvester cancer expert endorses FDA approval of new drug
Blog
Jul 1, 2024, 09:17
Medigene Reports Results of Annual General Meeting
Blog
Jul 1, 2024, 09:12
Agenus - CTEP has announced the availability of botensilimab, for clinical studies
Blog
Jul 1, 2024, 08:21
Karen Knudsen: MCEDAct creates a pathway to ensure timely Medicare coverage
Blog
Jul 1, 2024, 08:08
CtDNA in early Colorectal cancer
Blog
Jul 1, 2024, 07:57
Raffaele Colombo: TOPO1i ADC after TOPO1i ADC?
Insight
Jul 1, 2024, 07:31
Dan Vahdat: Digital-first cancer care for all
Blog
Jul 1, 2024, 06:50
Am I Doing Enough? - Pat Garcia-Gonzalez
Insight
Jul 1, 2024, 06:22
Partnership with Novartis for over 20 years - The Max Foundation
Insight
Jul 1, 2024, 06:11
Conquer Cancer has awarded more than $11 million to physician-scientists at the ASCO Annual Meeting
Drugs
Jul 1, 2024, 06:09
FDA has approved EPKINLY for the treatment of adults with relapsed/refractory follicular lymphoma - Genmab
Insight
Jul 1, 2024, 05:52
The final showcase event of PROTECT-EUROPE and SmartCARE - ECO